Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Female Sexual Dysfunction: Prescription Drug Pipeline Overview' returned 6 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues   Datamonitor, March 2010, Pages: 194 in these markets. Scope -Overview of erectile dysfunction, premature ejaculation and female sexual dysfunction disorders including epidemiology and key unmet needs. -Summary of the drug classes currently used U.S. Sexual Dysfunction Medication Markets   Frost & Sullivan, Sep 2003 and female sexual dysfunctions that can be treated with similar drug formulations provide pharmaceutical companies with an expanding patient base and doubled sales in the same class of medication. For example Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016   GlobalData, April 2010, Pages: 41 Sexual Dysfunction Portfolio 6.2 Catalysis SL 6.2.1 Company overview 6.2.2 Female Sexual Dysfunction Portfolio 7 Polycystic Ovarian Syndrome Market: Appendix 7.1 Definitions 7.2 Acronyms 7 Worldwide Prescription Drug Market for Womens Health: Now and Future 2004-2009   Fuji-Keizai USA, Inc., Feb 2005, Pages: 151 Related Drug R&D Pipeline & Commercial Implication 2.7.5 Important Finding (Special Note) 2.8 Female Sexual Dysfunction 2.8.1 Overview 2.8.2 Female Sexual Dysfunction Incidence, Prevalence, Mortality Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017   GlobalData, Sep 2010, Pages: 40 Market 7.1 Merck KGaA 7.1.1 Company Overview 7.1.2 Business Description 7.1.3 Female Sexual Dysfunction Portfolio 7.2 Catalysis SL 7.2.1 Company overview 7.2.2 Female Sexual Dysfunction Portfolio 8 The World Market for Gynaecology, 2007-2017   Spectra Intelligence, Sep 2007, Pages: 350 to provide an expert analysis of the prescription drug market for female health over the next decade based on current industrial insights, market factors and forces, and trend information. Study objectives Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network